Abstract
A minority of patients with gastroesophageal adenocarcinoma derive benefit from immune-checkpoint inhibition (ICI). In a large-cohort phase III study, the nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) arm (which was based on promising preliminary data from CheckMate 032) was closed owing to unacceptably high levels of mortality and morbidity. Our quest for better biomarkers than programmed cell death 1 ligand 1 (PD-L1) and safer dual ICI strategies must continue.
Original language | English (US) |
---|---|
Pages (from-to) | 9-10 |
Number of pages | 2 |
Journal | Nature Reviews Clinical Oncology |
Volume | 16 |
Issue number | 1 |
DOIs |
|
State | Published - Jan 1 2019 |
ASJC Scopus subject areas
- Oncology